{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T22:25:05Z","timestamp":1769898305259,"version":"3.49.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1016\/j.bpg.2005.05.007","type":"journal-article","created":{"date-parts":[[2005,10,26]],"date-time":"2005-10-26T11:24:07Z","timestamp":1130325847000},"page":"705-715","source":"Crossref","is-referenced-by-count":34,"title":["Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome)"],"prefix":"10.1016","volume":"19","author":[{"given":"W.W.","family":"de Herder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpg.2005.05.007_bib1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(63)90951-6","article-title":"The classification of carcinoid tumours","volume":"i","author":"Williams","year":"1963","journal-title":"Lancet"},{"issue":"supplement 3","key":"10.1016\/j.bpg.2005.05.007_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000201197","article-title":"Revised classification of neuroendocrine tumours of the lung, pancreas and gut","volume":"55","author":"Capella","year":"1994","journal-title":"Digestion"},{"key":"10.1016\/j.bpg.2005.05.007_bib3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1210\/er.2003-0014","article-title":"The diagnosis and medical management of advanced neuroendocrine tumours","volume":"25","author":"Kaltsas","year":"2004","journal-title":"Endocrinol Rev"},{"key":"10.1016\/j.bpg.2005.05.007_bib4","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1023\/A:1012272314550","article-title":"Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients","volume":"12","author":"Quaedvlieg","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bpg.2005.05.007_bib5","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/bjc.1994.424","article-title":"The epidemiology of carcinoid tumours in England and Scotland","volume":"70","author":"Newton","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bpg.2005.05.007_bib6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/1097-0142(19950701)76:1<106::AID-CNCR2820760116>3.0.CO;2-W","article-title":"Carcinoid tumors in Denmark 1978\u20131989 and the risk of subsequent cancers. A population-based study","volume":"76","author":"Westergaard","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.bpg.2005.05.007_bib7","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1054\/bjoc.2000.1394","article-title":"Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974\u201397","volume":"83","author":"Levi","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bpg.2005.05.007_bib8","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.1987.5.10.1502","article-title":"Karnofsky memorial lecture. An odyssey in the land of small tumors","volume":"5","author":"Moertel","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bpg.2005.05.007_bib9","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2","article-title":"An analysis of 8305 cases of carcinoid tumors","volume":"79","author":"Modlin","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.bpg.2005.05.007_bib10","first-page":"427","article-title":"The incidence, management, and outcome of patients with gastrointestinal carcinoids and second primary malignancies","volume":"180","author":"Gerstle","year":"1995","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.bpg.2005.05.007_bib11","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJM199903183401107","article-title":"Carcinoid tumors","volume":"340","author":"Kulke","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2005.05.007_bib12","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0140-6736(98)02286-7","article-title":"Carcinoid tumour","volume":"352","author":"Caplin","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2005.05.007_bib13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/BF01658532","article-title":"Surgical treatment of mid-gut carcinoid tumors","volume":"14","author":"Makridis","year":"1990","journal-title":"World J Surg"},{"key":"10.1016\/j.bpg.2005.05.007_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0378-4347(00)00341-8","article-title":"Clinical chemistry of serotonin and metabolites","volume":"747","author":"Kema","year":"2000","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1016\/j.bpg.2005.05.007_bib15","first-page":"425","article-title":"Karzinoide Tumoren des Dunndarms","volume":"1","author":"Obendorfer","year":"1907","journal-title":"Frank Z Pathol"},{"key":"10.1016\/j.bpg.2005.05.007_bib16","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0002-8703(54)90152-0","volume":"47","author":"Thorson","year":"1954","journal-title":"Am Heart J"},{"key":"10.1016\/j.bpg.2005.05.007_bib17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000080737","article-title":"Complications of midgut carcinoid tumors and carcinoid syndrome","volume":"80","author":"van der Horst-Schrivers","year":"2004","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.bpg.2005.05.007_bib18","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/clinchem\/46.10.1588","article-title":"Discriminating capacity of indole markers in the diagnosis of carcinoid tumors","volume":"46","author":"Meijer","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.bpg.2005.05.007_bib19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s002689900022","article-title":"Clinical manifestations of carcinoid disease","volume":"20","author":"Bax","year":"1996","journal-title":"World J Surg"},{"key":"10.1016\/j.bpg.2005.05.007_bib20","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/0016-5085(94)90008-6","article-title":"A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea","volume":"106","author":"von der Ohe","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2005.05.007_bib21","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1056\/NEJM199310073291503","article-title":"Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea","volume":"329","author":"von der Ohe","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2005.05.007_bib22","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3109\/00365528708991954","article-title":"Motilin in plasma and tumor tissues from patients with the carcinoid syndrome. Possible involvement in the increased frequency of bowel movements","volume":"22","author":"Oberg","year":"1987","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.bpg.2005.05.007_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01969085","article-title":"Histamine in carcinoid syndrome","volume":"25","author":"Gustafsen","year":"1988","journal-title":"Agents Actions"},{"key":"10.1016\/j.bpg.2005.05.007_bib24","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1136\/gut.28.11.1417","article-title":"Bradykinin in carcinoid syndrome","volume":"28","author":"Gustafsen","year":"1987","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2005.05.007_bib25","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/0016-5085(95)90447-6","article-title":"Serotonin, catecholamines, and spontaneous midgut carcinoid flush: plasma studies from flushing and nonflushing sites","volume":"108","author":"Matuchansky","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2005.05.007_bib26","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/0277-5379(87)90264-1","article-title":"Tachykinin production by carcinoid tumours in culture","volume":"23","author":"Norheim","year":"1987","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.bpg.2005.05.007_bib27","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/0016-5085(86)90630-X","article-title":"Serotonin release into blood after food and pentagastrin. Studies in healthy subjects and in patients with metastatic carcinoid tumors","volume":"91","author":"Richter","year":"1986","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2005.05.007_bib28","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/cncr.11226","article-title":"Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor","volume":"97","author":"Zuetenhorst","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bpg.2005.05.007_bib29","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/S0002-9440(10)64497-5","article-title":"Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells","volume":"161","author":"Xu","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bpg.2005.05.007_bib30","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0002-9440(10)64489-6","article-title":"Serotonin mechanisms in heart valve disease. I. Serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells","volume":"161","author":"Jian","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bpg.2005.05.007_bib31","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa021451","article-title":"Factors associated with progression of carcinoid heart disease","volume":"348","author":"Moller","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2005.05.007_bib32","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/01.CIR.92.4.790","article-title":"Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography","volume":"92","author":"Robiolio","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.bpg.2005.05.007_bib33","first-page":"499","article-title":"Ileal carcinoid tumors and intestinal ischemia","volume":"41","author":"Strobbe","year":"1994","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.bpg.2005.05.007_bib34","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1007\/s002680010232","article-title":"Method for dissection of mesenteric metastases in mid-gut carcinoid tumors","volume":"24","author":"Ohrvall","year":"2000","journal-title":"World J Surg"},{"key":"10.1016\/j.bpg.2005.05.007_bib35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/clinchem\/40.1.86","article-title":"Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors","volume":"40","author":"Kema","year":"1994","journal-title":"Clin Chem"},{"key":"10.1016\/j.bpg.2005.05.007_bib36","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1373\/49.4.586","article-title":"Catecholamine-synthesizing enzymes in carcinoid tumors and pheochromocytomas","volume":"49","author":"Meijer","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.bpg.2005.05.007_bib37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000051870","article-title":"Prognostic value of heart rate variability analysis in patients with carcinoid syndrome","volume":"63","author":"Hoffmann","year":"2001","journal-title":"Digestion"},{"key":"10.1016\/j.bpg.2005.05.007_bib38","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/bjs.1800810725","article-title":"Prognostic variables in patients with gastrointestinal carcinoid tumours","volume":"81","author":"McDermott","year":"1994","journal-title":"Br J Surg"},{"key":"10.1016\/j.bpg.2005.05.007_bib39","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1677\/erc.0.0100459","article-title":"The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut","volume":"10","author":"Ardill","year":"2003","journal-title":"Endocrinol Relat Cancer"},{"key":"10.1016\/j.bpg.2005.05.007_bib40","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1210\/jc.82.8.2622","article-title":"Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones","volume":"82","author":"Nobels","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpg.2005.05.007_bib41","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1515\/CCLM.1998.147","article-title":"Usefulness of chromogranin A as a marker for detection of relapses of carcinoid tumours","volume":"36","author":"Pirker","year":"1998","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.bpg.2005.05.007_bib42","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/clinchem\/38.4.534","article-title":"Improved diagnosis of carcinoid tumors by measurement of platelet serotonin","volume":"38","author":"Kema","year":"1992","journal-title":"Clin Chem"},{"key":"10.1016\/j.bpg.2005.05.007_bib43","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3109\/02841858709177396","article-title":"Angiography, computed tomography, magnetic resonance imaging and ultrasonography in detection of liver metastases from endocrine gastrointestinal tumours","volume":"28","author":"Andersson","year":"1987","journal-title":"Acta Radiol"},{"key":"10.1016\/j.bpg.2005.05.007_bib44","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/00000658-198712000-00007","article-title":"Percutaneous ultrasonography-guided cutting biopsy from liver metastases of endocrine gastrointestinal tumors","volume":"206","author":"Andersson","year":"1987","journal-title":"Ann Surg"},{"key":"10.1016\/j.bpg.2005.05.007_bib45","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/02841859509173390","article-title":"Midgut carcinoid tumours. CT appearance","volume":"36","author":"Sugimoto","year":"1995","journal-title":"Acta Radiol"},{"key":"10.1016\/j.bpg.2005.05.007_bib46","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2214\/ajr.143.3.581","article-title":"Computed tomography of abdominal carcinoid tumors","volume":"143","author":"Picus","year":"1984","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.bpg.2005.05.007_bib47","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00004728-198501000-00008","article-title":"Computed tomography of abdominal carcinoid tumor","volume":"9","author":"Cockey","year":"1985","journal-title":"J Comput Assist Tomogr"},{"key":"10.1016\/j.bpg.2005.05.007_bib48","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1210\/er.2002-0007","article-title":"Peptide receptors as molecular targets for cancer diagnosis and therapy","volume":"24","author":"Reubi","year":"2003","journal-title":"Endocrinol Rev"},{"key":"10.1016\/j.bpg.2005.05.007_bib49","first-page":"5969","article-title":"Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas","volume":"50","author":"Reubi","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.bpg.2005.05.007_bib50","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1677\/erc.0.0100451","article-title":"Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours","volume":"10","author":"de Herder","year":"2003","journal-title":"Endocrinol Relat Cancer"},{"key":"10.1016\/j.bpg.2005.05.007_bib51","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0950-3528(96)90014-7","article-title":"Peptide receptors in gut endocrine tumours","volume":"10","author":"de Herder","year":"1996","journal-title":"Baillieres Clin Gastroenterol"},{"key":"10.1016\/j.bpg.2005.05.007_bib52","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance","volume":"24","author":"Hofland","year":"2003","journal-title":"Endocrinol Rev"},{"key":"10.1016\/j.bpg.2005.05.007_bib53","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s002689900024","article-title":"Somatostatin receptor scintigraphy in patients with carcinoid tumors","volume":"20","author":"Kwekkeboom","year":"1996","journal-title":"World J Surg"},{"key":"10.1016\/j.bpg.2005.05.007_bib54","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/0959-8049(96)00241-9","article-title":"Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours","volume":"32A","author":"Taal","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bpg.2005.05.007_bib55","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1148\/radiology.220.2.r01au25373","article-title":"Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors","volume":"220","author":"Hoegerle","year":"2001","journal-title":"Radiology"},{"key":"10.1016\/j.bpg.2005.05.007_bib56","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1200\/JCO.1998.16.7.2534","article-title":"Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors","volume":"16","author":"Orlefors","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bpg.2005.05.007_bib57","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s002590050197","article-title":"Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours","volume":"25","author":"Adams","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.bpg.2005.05.007_bib58","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3109\/00365528609011123","article-title":"Ketanserin versus placebo in carcinoid syndrome. A clinical controlled trial","volume":"21","author":"Gustafsen","year":"1986","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.bpg.2005.05.007_bib59","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0959-8049(98)00009-4","article-title":"Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome","volume":"34","author":"Wymenga","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bpg.2005.05.007_bib60","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1136\/gut.42.5.628","article-title":"Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea","volume":"42","author":"Saslow","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2005.05.007_bib61","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1053\/gast.1996.v110.pm8566586","article-title":"Relation between fat malabsorption and transit abnormalities in human carcinoid diarrhea","volume":"110","author":"Saslow","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2005.05.007_bib62","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/bmj.296.6623.682-a","article-title":"Inhibitory effects of ranitidine on flushing and serum serotonin concentrations in carcinoid syndrome","volume":"296","author":"Noppen","year":"1988","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.bpg.2005.05.007_bib63","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/pgmj.72.849.403","article-title":"Somatostatin analogue treatment of neuroendocrine tumours","volume":"72","author":"de Herder","year":"1996","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.bpg.2005.05.007_bib64","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1200\/JCO.1999.17.4.1111","article-title":"Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms","volume":"17","author":"Wymenga","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bpg.2005.05.007_bib65","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","author":"O'Toole","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.bpg.2005.05.007_bib66","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/gut.39.2.279","article-title":"Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients","volume":"39","author":"Ruszniewski","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2005.05.007_bib67","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1023\/A:1008205415035","article-title":"High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects","volume":"8","author":"Eriksson","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bpg.2005.05.007_bib68","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0950-3528(96)90021-4","article-title":"Gastrointestinal endocrine tumours: medical management","volume":"10","author":"Arnold","year":"1996","journal-title":"Baillieres Clin Gastroenterol"},{"key":"10.1016\/j.bpg.2005.05.007_bib69","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/gut.38.3.430","article-title":"Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours","volume":"38","author":"Arnold","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2005.05.007_bib70","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/1097-0142(19930701)72:1<244::AID-CNCR2820720143>3.0.CO;2-Q","article-title":"Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors","volume":"72","author":"Saltz","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.bpg.2005.05.007_bib71","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bpg.2005.05.007_bib72","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00000421-200008000-00020","article-title":"Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors","volume":"23","author":"Ricci","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.bpg.2005.05.007_bib73","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1159\/000007693","article-title":"Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors","volume":"60","author":"Faiss","year":"1999","journal-title":"Digestion"},{"key":"10.1016\/j.bpg.2005.05.007_bib74","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM199601253340408","article-title":"Octreotide","volume":"334","author":"Lamberts","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2005.05.007_bib75","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/eje.0.1510107","article-title":"High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours","volume":"151","author":"Welin","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.bpg.2005.05.007_bib76","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3109\/02841869109092413","article-title":"Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide","volume":"30","author":"Creutzfeldt","year":"1991","journal-title":"Acta Oncol"},{"key":"10.1016\/j.bpg.2005.05.007_bib77","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0002-9270(99)00146-X","article-title":"Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors","volume":"94","author":"Frank","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"supplement 1","key":"10.1016\/j.bpg.2005.05.007_bib78","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000051862","article-title":"Interferon in the management of neuroendocrine GEP-tumors: a review","volume":"62","author":"Oberg","year":"2000","journal-title":"Digestion"},{"key":"10.1016\/j.bpg.2005.05.007_bib79","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bjs.4149","article-title":"Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours","volume":"90","author":"Kolby","year":"2003","journal-title":"Br J Surg"},{"key":"10.1016\/j.bpg.2005.05.007_bib80","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ctrv.2003.07.002","article-title":"Adding interferon-alpha to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours","volume":"29","author":"Pape","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bpg.2005.05.007_bib81","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/0735-1097(94)00374-Y","article-title":"Outcome of cardiac surgery for carcinoid heart disease","volume":"25","author":"Connolly","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.bpg.2005.05.007_bib82","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0002-9149(99)80586-4","article-title":"Predictors of outcome of tricuspid valve replacement in carcinoid heart disease","volume":"75","author":"Robiolio","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.bpg.2005.05.007_bib83","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1056\/NEJM198511073131916","article-title":"Rapid reversal of carcinoid crisis with a somatostatin analogue","volume":"313","author":"Kvols","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2005.05.007_bib84","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s001340050060","article-title":"Carcinoid crisis during transesophageal echocardiography","volume":"26","author":"Janssen","year":"2000","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.bpg.2005.05.007_bib85","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/bja\/aeh135","article-title":"Remifentanil and anaesthesia for carcinoid syndrome","volume":"92","author":"Farling","year":"2004","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bpg.2005.05.007_bib86","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.1984.2.11.1255","article-title":"Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor","volume":"2","author":"Engstrom","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bpg.2005.05.007_bib87","first-page":"665","article-title":"Evaluation of combined cyclophosphamide and methotrexate therapy in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome","volume":"68","author":"Moertel","year":"1984","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.bpg.2005.05.007_bib88","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/oxfordjournals.annonc.a059049","article-title":"A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (ITMO) Group","volume":"6","author":"Di Bartolomeo","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bpg.2005.05.007_bib89","first-page":"327","article-title":"Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome","volume":"2","author":"Moertel","year":"1979","journal-title":"Cancer Clin Trials"},{"key":"10.1016\/j.bpg.2005.05.007_bib90","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00000421-198808000-00015","article-title":"A phase II trial of streptozotocin and adriamycin in advanced APUD tumors","volume":"11","author":"Frame","year":"1988","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.bpg.2005.05.007_bib91","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","article-title":"Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin","volume":"81","author":"Mitry","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bpg.2005.05.007_bib92","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdf064","article-title":"Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours","volume":"13","author":"Bajetta","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bpg.2005.05.007_bib93","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V","article-title":"Treatment with cisplatin and etoposide in patients with neuroendocrine tumors","volume":"92","author":"Fjallskog","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.bpg.2005.05.007_bib94","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00000421-199806000-00005","article-title":"Dacarbazine, fluorouracil, and leucovorin in patients with advanced neuroendocrine tumors: a phase II trial","volume":"21","author":"Ollivier","year":"1998","journal-title":"Am J Clin Oncol"},{"issue":"supplement 1","key":"10.1016\/j.bpg.2005.05.007_bib95","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000051859","article-title":"Chemotherapy in the treatment of neuroendocrine malignant tumors","volume":"62","author":"Rougier","year":"2000","journal-title":"Digestion"}],"container-title":["Best Practice &amp; Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691805000910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691805000910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T14:00:45Z","timestamp":1586527245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691805000910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":95,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S1521691805000910"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2005.05.007","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}